← Back to patent-cliff list
MN-08
Tier C — Watch / tradeMN-08
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NMDAR, 5-HT3
Indications (approved)：Hypertension, Alzheimer's disease, Pulmonary arterial hypertension, Ocular hypertension, Open-angle glaucoma, 血管性痴呆, Glaucoma, Idiopathic pulmonary arterial hypertension
Regional status
US
-
EU
-
China
Phase II
2021-12-31
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of MN-08?
Approved indications include: Hypertension, Alzheimer's disease, Pulmonary arterial hypertension, Ocular hypertension, Open-angle glaucoma, 血管性痴呆, Glaucoma, Idiopathic pulmonary arterial hypertension.
When does the MN-08 patent expire?
No public expiry year is available for MN-08 yet; this page updates once verified.
How do I get a quote for MN-08 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06